Financhill
Buy
60

TRUMF Quote, Financials, Valuation and Earnings

Last price:
$16.14
Seasonality move :
5.97%
Day range:
$16.14 - $18.08
52-week range:
$15.32 - $22.26
Dividend yield:
0.97%
P/E ratio:
34.52x
P/S ratio:
3.90x
P/B ratio:
2.93x
Volume:
1.2K
Avg. volume:
4.5K
1-year change:
0.09%
Market cap:
$26.8B
Revenue:
$6.8B
EPS (TTM):
$0.53

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
TRUMF
Terumo
-- -- -- -- --
AMGXF
AnGes
-- -- -- -- --
HLOSF
Healios KK
-- -- -- -- --
PPTDF
PeptiDream
-- -- -- -- --
SOLTF
Nxera Pharma
-- -- -- -- --
TAK
Takeda Pharmaceutical
$7.9B -- 0.17% -- $17.12
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
TRUMF
Terumo
$18.14 -- $26.8B 34.52x $0.09 0.97% 3.90x
AMGXF
AnGes
$0.36 -- $117.8M -- $0.00 0% 22.97x
HLOSF
Healios KK
$2.70 -- $273.9M -- $0.00 0% 65.28x
PPTDF
PeptiDream
$11.34 -- $1.5B 14.08x $0.00 0% 4.86x
SOLTF
Nxera Pharma
$6.20 -- $557.4M -- $0.00 0% 3.11x
TAK
Takeda Pharmaceutical
$14.68 $17.12 $46.4B 67.28x $0.34 4.53% 1.57x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
TRUMF
Terumo
11.33% 0.852 4.6% 1.67x
AMGXF
AnGes
-- 1.066 -- 1.28x
HLOSF
Healios KK
51.17% -1.190 6.95% 1.11x
PPTDF
PeptiDream
25.74% 0.249 5.48% 4.62x
SOLTF
Nxera Pharma
48.1% 2.008 78.18% 2.83x
TAK
Takeda Pharmaceutical
39.43% -0.344 64.47% 0.45x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
TRUMF
Terumo
$951.4M $300.1M 7.51% 8.56% 17.57% $215.3M
AMGXF
AnGes
$368.5K -$8.2M -33.92% -33.92% -741.83% --
HLOSF
Healios KK
$59K -$4.9M -85.83% -196.15% -1239.47% -$5.1M
PPTDF
PeptiDream
$9.6M -$9M 23.58% 34.1% -29.18% -$69.4M
SOLTF
Nxera Pharma
$33M -$14.4M -4.28% -8.65% -28.7% -$14.8M
TAK
Takeda Pharmaceutical
$4.4B $272.4M 0.89% 1.49% -12.32% $854.8M

Terumo vs. Competitors

  • Which has Higher Returns TRUMF or AMGXF?

    AnGes has a net margin of 13.44% compared to Terumo's net margin of -737.34%. Terumo's return on equity of 8.56% beat AnGes's return on equity of -33.92%.

    Company Gross Margin Earnings Per Share Invested Capital
    TRUMF
    Terumo
    55.06% $0.16 $10.3B
    AMGXF
    AnGes
    33.2% -$0.03 $21.5M
  • What do Analysts Say About TRUMF or AMGXF?

    Terumo has a consensus price target of --, signalling downside risk potential of --. On the other hand AnGes has an analysts' consensus of -- which suggests that it could fall by --. Given that Terumo has higher upside potential than AnGes, analysts believe Terumo is more attractive than AnGes.

    Company Buy Ratings Hold Ratings Sell Ratings
    TRUMF
    Terumo
    0 0 0
    AMGXF
    AnGes
    0 0 0
  • Is TRUMF or AMGXF More Risky?

    Terumo has a beta of 0.840, which suggesting that the stock is 16.009% less volatile than S&P 500. In comparison AnGes has a beta of -0.088, suggesting its less volatile than the S&P 500 by 108.837%.

  • Which is a Better Dividend Stock TRUMF or AMGXF?

    Terumo has a quarterly dividend of $0.09 per share corresponding to a yield of 0.97%. AnGes offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Terumo pays 30.45% of its earnings as a dividend. AnGes pays out -- of its earnings as a dividend. Terumo's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios TRUMF or AMGXF?

    Terumo quarterly revenues are $1.7B, which are larger than AnGes quarterly revenues of $1.1M. Terumo's net income of $232.2M is higher than AnGes's net income of -$8.2M. Notably, Terumo's price-to-earnings ratio is 34.52x while AnGes's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Terumo is 3.90x versus 22.97x for AnGes. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    TRUMF
    Terumo
    3.90x 34.52x $1.7B $232.2M
    AMGXF
    AnGes
    22.97x -- $1.1M -$8.2M
  • Which has Higher Returns TRUMF or HLOSF?

    Healios KK has a net margin of 13.44% compared to Terumo's net margin of -6742.11%. Terumo's return on equity of 8.56% beat Healios KK's return on equity of -196.15%.

    Company Gross Margin Earnings Per Share Invested Capital
    TRUMF
    Terumo
    55.06% $0.16 $10.3B
    HLOSF
    Healios KK
    23.68% -$0.18 $26.9M
  • What do Analysts Say About TRUMF or HLOSF?

    Terumo has a consensus price target of --, signalling downside risk potential of --. On the other hand Healios KK has an analysts' consensus of -- which suggests that it could fall by --. Given that Terumo has higher upside potential than Healios KK, analysts believe Terumo is more attractive than Healios KK.

    Company Buy Ratings Hold Ratings Sell Ratings
    TRUMF
    Terumo
    0 0 0
    HLOSF
    Healios KK
    0 0 0
  • Is TRUMF or HLOSF More Risky?

    Terumo has a beta of 0.840, which suggesting that the stock is 16.009% less volatile than S&P 500. In comparison Healios KK has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

  • Which is a Better Dividend Stock TRUMF or HLOSF?

    Terumo has a quarterly dividend of $0.09 per share corresponding to a yield of 0.97%. Healios KK offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Terumo pays 30.45% of its earnings as a dividend. Healios KK pays out -- of its earnings as a dividend. Terumo's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios TRUMF or HLOSF?

    Terumo quarterly revenues are $1.7B, which are larger than Healios KK quarterly revenues of $249.2K. Terumo's net income of $232.2M is higher than Healios KK's net income of -$16.8M. Notably, Terumo's price-to-earnings ratio is 34.52x while Healios KK's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Terumo is 3.90x versus 65.28x for Healios KK. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    TRUMF
    Terumo
    3.90x 34.52x $1.7B $232.2M
    HLOSF
    Healios KK
    65.28x -- $249.2K -$16.8M
  • Which has Higher Returns TRUMF or PPTDF?

    PeptiDream has a net margin of 13.44% compared to Terumo's net margin of -24.41%. Terumo's return on equity of 8.56% beat PeptiDream's return on equity of 34.1%.

    Company Gross Margin Earnings Per Share Invested Capital
    TRUMF
    Terumo
    55.06% $0.16 $10.3B
    PPTDF
    PeptiDream
    34.69% -$0.05 $493M
  • What do Analysts Say About TRUMF or PPTDF?

    Terumo has a consensus price target of --, signalling downside risk potential of --. On the other hand PeptiDream has an analysts' consensus of -- which suggests that it could fall by --. Given that Terumo has higher upside potential than PeptiDream, analysts believe Terumo is more attractive than PeptiDream.

    Company Buy Ratings Hold Ratings Sell Ratings
    TRUMF
    Terumo
    0 0 0
    PPTDF
    PeptiDream
    0 0 0
  • Is TRUMF or PPTDF More Risky?

    Terumo has a beta of 0.840, which suggesting that the stock is 16.009% less volatile than S&P 500. In comparison PeptiDream has a beta of 0.523, suggesting its less volatile than the S&P 500 by 47.679%.

  • Which is a Better Dividend Stock TRUMF or PPTDF?

    Terumo has a quarterly dividend of $0.09 per share corresponding to a yield of 0.97%. PeptiDream offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Terumo pays 30.45% of its earnings as a dividend. PeptiDream pays out -- of its earnings as a dividend. Terumo's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios TRUMF or PPTDF?

    Terumo quarterly revenues are $1.7B, which are larger than PeptiDream quarterly revenues of $27.8M. Terumo's net income of $232.2M is higher than PeptiDream's net income of -$6.8M. Notably, Terumo's price-to-earnings ratio is 34.52x while PeptiDream's PE ratio is 14.08x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Terumo is 3.90x versus 4.86x for PeptiDream. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    TRUMF
    Terumo
    3.90x 34.52x $1.7B $232.2M
    PPTDF
    PeptiDream
    4.86x 14.08x $27.8M -$6.8M
  • Which has Higher Returns TRUMF or SOLTF?

    Nxera Pharma has a net margin of 13.44% compared to Terumo's net margin of -11.44%. Terumo's return on equity of 8.56% beat Nxera Pharma's return on equity of -8.65%.

    Company Gross Margin Earnings Per Share Invested Capital
    TRUMF
    Terumo
    55.06% $0.16 $10.3B
    SOLTF
    Nxera Pharma
    75.69% -$0.06 $863.6M
  • What do Analysts Say About TRUMF or SOLTF?

    Terumo has a consensus price target of --, signalling downside risk potential of --. On the other hand Nxera Pharma has an analysts' consensus of -- which suggests that it could fall by --. Given that Terumo has higher upside potential than Nxera Pharma, analysts believe Terumo is more attractive than Nxera Pharma.

    Company Buy Ratings Hold Ratings Sell Ratings
    TRUMF
    Terumo
    0 0 0
    SOLTF
    Nxera Pharma
    0 0 0
  • Is TRUMF or SOLTF More Risky?

    Terumo has a beta of 0.840, which suggesting that the stock is 16.009% less volatile than S&P 500. In comparison Nxera Pharma has a beta of 0.374, suggesting its less volatile than the S&P 500 by 62.646%.

  • Which is a Better Dividend Stock TRUMF or SOLTF?

    Terumo has a quarterly dividend of $0.09 per share corresponding to a yield of 0.97%. Nxera Pharma offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Terumo pays 30.45% of its earnings as a dividend. Nxera Pharma pays out -- of its earnings as a dividend. Terumo's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios TRUMF or SOLTF?

    Terumo quarterly revenues are $1.7B, which are larger than Nxera Pharma quarterly revenues of $43.6M. Terumo's net income of $232.2M is higher than Nxera Pharma's net income of -$5M. Notably, Terumo's price-to-earnings ratio is 34.52x while Nxera Pharma's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Terumo is 3.90x versus 3.11x for Nxera Pharma. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    TRUMF
    Terumo
    3.90x 34.52x $1.7B $232.2M
    SOLTF
    Nxera Pharma
    3.11x -- $43.6M -$5M
  • Which has Higher Returns TRUMF or TAK?

    Takeda Pharmaceutical has a net margin of 13.44% compared to Terumo's net margin of -9.79%. Terumo's return on equity of 8.56% beat Takeda Pharmaceutical's return on equity of 1.49%.

    Company Gross Margin Earnings Per Share Invested Capital
    TRUMF
    Terumo
    55.06% $0.16 $10.3B
    TAK
    Takeda Pharmaceutical
    63.73% -$0.21 $76.5B
  • What do Analysts Say About TRUMF or TAK?

    Terumo has a consensus price target of --, signalling downside risk potential of --. On the other hand Takeda Pharmaceutical has an analysts' consensus of $17.12 which suggests that it could grow by 16.6%. Given that Takeda Pharmaceutical has higher upside potential than Terumo, analysts believe Takeda Pharmaceutical is more attractive than Terumo.

    Company Buy Ratings Hold Ratings Sell Ratings
    TRUMF
    Terumo
    0 0 0
    TAK
    Takeda Pharmaceutical
    3 1 0
  • Is TRUMF or TAK More Risky?

    Terumo has a beta of 0.840, which suggesting that the stock is 16.009% less volatile than S&P 500. In comparison Takeda Pharmaceutical has a beta of 0.223, suggesting its less volatile than the S&P 500 by 77.69%.

  • Which is a Better Dividend Stock TRUMF or TAK?

    Terumo has a quarterly dividend of $0.09 per share corresponding to a yield of 0.97%. Takeda Pharmaceutical offers a yield of 4.53% to investors and pays a quarterly dividend of $0.34 per share. Terumo pays 30.45% of its earnings as a dividend. Takeda Pharmaceutical pays out 280.28% of its earnings as a dividend. Terumo's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but Takeda Pharmaceutical's is not.

  • Which has Better Financial Ratios TRUMF or TAK?

    Terumo quarterly revenues are $1.7B, which are smaller than Takeda Pharmaceutical quarterly revenues of $6.9B. Terumo's net income of $232.2M is higher than Takeda Pharmaceutical's net income of -$676.5M. Notably, Terumo's price-to-earnings ratio is 34.52x while Takeda Pharmaceutical's PE ratio is 67.28x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Terumo is 3.90x versus 1.57x for Takeda Pharmaceutical. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    TRUMF
    Terumo
    3.90x 34.52x $1.7B $232.2M
    TAK
    Takeda Pharmaceutical
    1.57x 67.28x $6.9B -$676.5M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

What Is the Ceiling for IONQ Stock?
What Is the Ceiling for IONQ Stock?

IonQ (NYSE:IONQ) is a quantum computing startup that, like many…

Can FUBO Stock Double?
Can FUBO Stock Double?

TV streaming service Fubo (NYSE:FUBO) has seen incredible returns so…

Where Will CoreWeave Stock Be in 1 Year?
Where Will CoreWeave Stock Be in 1 Year?

When CoreWeave (NASDAQ: CRWV) slipped below its $40 IPO price…

Stock Ideas

Buy
69
Is NVDA Stock a Buy?

Market Cap: $4T
P/E Ratio: 56x

Buy
62
Is MSFT Stock a Buy?

Market Cap: $3.7T
P/E Ratio: 43x

Sell
45
Is AAPL Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 35x

Alerts

Buy
58
INKT alert for Jul 12

MiNK Therapeutics [INKT] is up 727.94% over the past day.

Buy
51
NEGG alert for Jul 12

Newegg Commerce [NEGG] is up 74.03% over the past day.

Buy
68
ATRO alert for Jul 12

Astronics [ATRO] is up 16.28% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock